“…ABP associated with transrectal prostate biopsy is becoming more common with an incidence rate in the range 0.6%-2.1% (Stoica et al, 2007;Miura et al, 2008;Shigehara et al, 2008;Brede and Shoskes, 2011). Also, fluoroquinolone-resistant strains of E. coli were observed in most cases (Stoica et al, 2007;Miura et al, 2008;Shigehara et al, 2008). A retrospective study by Shigehara et al showed that a risk factor of fluoroquinoloneresistant E. coli may have been caused by the use of levofloxacin for prophylactic treatment, and to avoid this strain from generating, patients should receive levofloxacin for a short period before biopsy (Shigehara et al, 2008).…”